Evotec (EVT) focused on their strategic business model, rather than their product pipeline, which
aims to create a high degree of efficiency with financial reward so that innovation can continue to
grow. They described their business approach as unique due to their one core platform, which
they apply to different business models on a fee for service basis. Officials noted their action plan
2022, which aims to increase their co-owned pipeline and grow their platform further. Evotec
indicated that their main focus going forward were small molecules and new modalities as these
are efficient and cost effective.
Officials summarized their one fully integrated platform that contains two types of partnered
drug discovery and development programs. Firstly, they described Evotec Execute, which is used
when their scientists work on intellectual property (IP) that belongs to their partners. Officials
noted their top quality and fully integrated R&D services with a comprehensive service panel
used for external innovation. They mentioned a few examples of Evotec executive alliances,
including their partnership with Roche focused on oncology.
Secondly, officials spoke about their Evotec Innovate business, which is used when their scientists
generate IP and subsequently work with external partners. They briefly recalled some of their
main partners for this including Sanofi for diabetes and Celgene for oncology. Evotec highlighted
their platform used in the drug discovery paradigm that leads to better translation. The platform
starts with medical records and patient induced pluripotent stem cell (iPSC) lines, it then moves
on to holistic profiles with large data sets and AI technology.
To conclude, Evotec moved on to financials where they showed a consistent increase in total
group revenue, R&D expenses and EBITDA over the past 3 years. They also announced that there
will be a dense flow of clinical news in 2019 from preclinical data to Phase II data from their
alliances including that with Bayer for chronic cough. In addition, there will be more news
regarding the $14m payment from Celgene for the advancement of a program using Evotec’s
iPSC screening platform.
aims to create a high degree of efficiency with financial reward so that innovation can continue to
grow. They described their business approach as unique due to their one core platform, which
they apply to different business models on a fee for service basis. Officials noted their action plan
2022, which aims to increase their co-owned pipeline and grow their platform further. Evotec
indicated that their main focus going forward were small molecules and new modalities as these
are efficient and cost effective.
Officials summarized their one fully integrated platform that contains two types of partnered
drug discovery and development programs. Firstly, they described Evotec Execute, which is used
when their scientists work on intellectual property (IP) that belongs to their partners. Officials
noted their top quality and fully integrated R&D services with a comprehensive service panel
used for external innovation. They mentioned a few examples of Evotec executive alliances,
including their partnership with Roche focused on oncology.
Secondly, officials spoke about their Evotec Innovate business, which is used when their scientists
generate IP and subsequently work with external partners. They briefly recalled some of their
main partners for this including Sanofi for diabetes and Celgene for oncology. Evotec highlighted
their platform used in the drug discovery paradigm that leads to better translation. The platform
starts with medical records and patient induced pluripotent stem cell (iPSC) lines, it then moves
on to holistic profiles with large data sets and AI technology.
To conclude, Evotec moved on to financials where they showed a consistent increase in total
group revenue, R&D expenses and EBITDA over the past 3 years. They also announced that there
will be a dense flow of clinical news in 2019 from preclinical data to Phase II data from their
alliances including that with Bayer for chronic cough. In addition, there will be more news
regarding the $14m payment from Celgene for the advancement of a program using Evotec’s
iPSC screening platform.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.